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We applied single nucleotide polymorphism arrays (SNP-A) to study karyotypic abnormalities in patients with atypical
myeloproliferative syndromes (MPD), including myeloproliferative/myelodysplastic syndrome overlap both positive and
negative for the JAK2 V617F mutation and secondary acute myeloid leukemia (AML). In typical MPD cases (N=8), which served
as a control group, those with a homozygous V617F mutation showed clear uniparental disomy (UPD) of 9p using SNP-A.
Consistent with possible genomic instability, in 19/30 MDS/MPD-U patients, we found additional lesions not identified by
metaphase cytogenetics. In addition to UPD9p, we also have detected UPD affecting other chromosomes, including 1 (2/30), 11
(4/30), 12 (1/30) and 22 (1/30). Transformation to AML was observed in 8/30 patients. In 5 V617F+ patients who progressed to
AML, we show that SNP-A can allow for the detection of two modes of transformation: leukemic blasts evolving from either
a wild-type jak2 precursor carrying other acquired chromosomal defects, or from a V617F+ mutant progenitor characterized by
UPD9p. SNP-A-based detection of cryptic lesions in MDS/MPD-U may help explain the clinical heterogeneity of this disorder.
Citation: Gondek LP, Dunbar AJ, Szpurka H, McDevitt MA, Maciejewski JP (2007) SNP Array Karyotyping Allows for the Detection of Uniparental
Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD. PLoS ONE 2(11): e1225. doi:10.1371/journal.pone.0001225
INTRODUCTION
Acquired loss of heterozygosity (LOH) can occur either as a result
of deletions or mitotic recombination (uniparental disomy [UPD]).
LOH has been described in many malignant hematologic
conditions including acute myelogenous leukemia (AML), as well
as solid cancers [1–5]. Using 50K single nucleotide polymorphism
arrays (SNP-A), we recently identified a high frequency of UPD in
myelodysplastic syndromes (MDS) as well, occurring in approx-
imately 30% of patients [6]. A similar result was subsequently
found in low-risk MDS subtypes [7]. Moreover, other previously
cryptic aberrations not detected by metaphase cytogenetics (MC)
were identified in all sub-types of MDS, including secondary
leukemias [6]. We have also extensively validated this technology
with regard to its sensitivity and resolution for detecting acquired
loss of heterozygosity, gains, and micro-deletions [8].
LOH can lead to decreased gene expression or hemi/
homozygosity of germ line variants or somatic mutations affecting
the remaining allele. One such example is JAK2 (*147796) V617F,
a gain-of-function mutation often associated with myeloprolifer-
ative syndromes (MPD), particularly polycythemia vera [9–13].
Studies using microsatellite markers, as opposed to other methods
such as MC or fluorescence in situ hybridization (FISH), which
cannot detect LOH due to UPD, have shown that UPD9p leads to
homozygosity of the V617F mutation [14]. The V617F mutation
has been rarely found in de novo AML [15–18], but has recently
been associated with MDS/MPD overlap syndromes and in some
cases, AML evolving from MPD [19,20].
The WHO classification of myeloid malignancies distinguishes
MDS/MPD as a separate entity and includes chronic myelomo-
nocytic leukemia (CMML), MDS/MPD-Unclassifiable (MDS/
MPD-U), and refractory anemia with ringed sideroblasts and
thrombocytosis (RARS-t) [21]. Analysis of a large cohort of these
patients has revealed that the V617F mutation is present in only
small proportion of these patients [20]. However, we have shown
recently that patients with RARS-t have a higher incidence of
V617F [22] suggesting that V617F genotyping and evaluation
would be useful in classification and clinical evaluation.
In addition, larger chromosomal abnormalities as detected by
metaphase cytogenetics are also common in patients with typical
MPD or MDS/MPD [23]. For example, 46% patients with
myelofibrosis demonstrated an abnormal metaphase karyotype
involving interstitial deletions of the long arm of chromosomes 13
or 20, among others [24]. In addition, MPD is the underlying
diagnosis in 5% of patients with 5q abnormalities [25], and in PV,
25.4% of patients showed clonal abnormalities. The recurrent
chromosomal lesions were those of chromosome 9 (21.1%),
del(20q) (19.2%), trisomy 8 (19.2%), rearrangements of 13q
(13.4%), and abnormalities of 1q (11.5%), chromosome 5 and
chromosome 7 (9.6%) [26].
We hypothesize that if cytogenetic methods with a higher
resolution are used, additional defects, including UPD of
chromosomal regions other than 9p, will be detected. Further-
more, we stipulate that SNP-A can allow for a convenient method
of identifying chromosomal changes in patients who transform to
AML.
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arrays (SNP-A) to examine genomic composition and identify
previously cryptic chromosomal defects and molecular abnormal-
ities in a group of patients with MDS/MPD-U and secondary
AML developed from MDS/MPD-U both positive and negative
for the V617F mutation. We hypothesize that while UPD9p leads
to homozygosity of the JAK2 mutation in MPD, other occurrences
of UPD on additional chromosomes in MDS/MPD-U patients
may contribute to the phenotypic features that give rise to this
ambiguous disease.
RESULTS
Detection of UPD9p in patients with MPD as
a demonstration of SNP-A to identify copy-neutral
LOH
First, we performed SNP-A karyotyping in 58 control marrows.
Normal copy number polymorphisms were easily detected and
excluded from the patient analysis along with any others
previously reported in the literature or on available internet
databases [27]. LOH was detected in 4/58 healthy controls and
tended to be smaller in size. Consequently, for the analysis of any
patients, these changes were not deemed significant and similar to
other lesions, were excluded from the analysis. Repeated analysis
of samples (N=6) showed high congruency (data not shown) and
analysis of SNP calls spanning chromosome X in males revealed
remarkable fidelity with an accuracy rate of .99% [8].
To determine whether or not SNP-A can be used as an accurate
and effective method to identify acquired UPD, we studied
patients with typical MPD homozygous for the V617F mutation.
In 4 control patients homozygous for V617F (Pts. #34, #36, #37
and #38, Tables 1 & 2), UPD9p was easily detected by SNP-A;
in addition, those positive control patients heterozygous for the
V617F mutation showed normal diploid copy number by SNP-A
(except for Pt. #31 with trisomy 9), and therefore lacked any
UPD9p (Figure 1). However, it is possible that an abnormal clone
harboring UPD9p exists in heterozygous V617F patients but is too
small to be detected using current methods. Regardless, similar to
results recently published [8,28], we have shown that SNP-A
provides a simple and effective tool for detecting acquired UPD.
Detection of cryptic chromosomal abnormalities in
MDS/MPD-U patients
Using SNP-A, clonal lesions, including segmental UPD, were
found in 23/30 (77%) patients as compared to 18/30 (60%) by
conventional metaphase cytogenetics (Table 2). All unbalanced
copy number changes found by MC were confirmed by SNP-A,
and in most instances, allowed for further refinement to more
isolated regions. UPD, including UPD9p, appears to be a common
chromosomal defect, occurring on chromosomes other than 9 in
8/30 patients (i.e. on chromosomes 1, 11, and 22) (Table 3). In
addition, other copy number changes were detected as well,
including segmental micro-deletions of chromosomes 1, 5, 9 and
12, among others (Table 2). Any shared/overlapping lesions
found in 3 or more patients were isolated and are indicated in
Table 4. Not surprisingly, the most common region of overlap was
that of 9p spanning the region of the jak2 gene. Likewise, other
common lesions often associated with these diseases were
identified, including del5q and trisomy 8. However, three
previously cryptic overlapping regions shared in 3 or more
patients were identified (Table 4). These regions consisted of
three small segmental deletions of chromosome 7 (7q22.1, 7q34,
and 7q36.1), a small cytoband (q14.1) of chromosome 11 (as
defined by patients #9, #11 and #13), and small sub-sections of
the q arm of chromosome 20 lying within the area of cytobands
q11.23 to q12 (as defined by patients #4, #11, #20, and #21).
Analysis of patients with MDS/MPD-U who progressed to
AML compared to those with a stable course of the disease
showed, as expected, a greater number of lesions detected in the
first group (8/8 vs. 15/22). Within cohorts studied, Kaplan-Meier
analysis of survival shows no difference between patients with or
without previously cryptic defects uncovered by SNP arrays (data
not shown).
Comparison of chromosomal abnormalities in
V617F+ and V617F- MDS/MPD-U
We have identified patients (Tables 1 & 2) with a history of
MDS/MPD-U both positive (N=12) and negative (N=18) for the
JAK2 V617F mutation and have analyzed them using 250K SNP-
A. Conventional MC revealed chromosomal aberrations in 9/12
(75%) of those positive for the mutation, including common
abnormalities such as +8 and del5q. A majority of the V617F+
MDS/MPD-U patients (7/9) with abnormal MC showed pre-
viously undetected additional lesions, including UPD on chromo-
somes other than 9 in only 1/12 patients (Table 2). Examples of
deleted regions in patients positive for the mutation include
segmental losses within chromosomes 2, 4, 5 and 20 and UPD on
chromosomes 1p and 9p. However, these micro-deletions and
instances of UPD appear to be highly variable from patient to
patient with no substantial overlap occurring between more than
two patients.
For those MDS/MPD-U patients negative for the V617F
mutation, previously undetected lesions were also identified by
SNP-A. Of these 18 patients, 9 showed abnormal MC. However,
when SNP-A was applied, 5 additional patients with normal MC
were found to have lesions, and 7 of the 9 patients with abnormal
MC had lesions in addition to those detected by MC. Examples of
these lesions include micro-deletions of chromosomes 6 and 20.
UPD was more common in V617F- patients, occurring in 7/18
patients, predominantly on chromosome 11 (in 4 of the 7 patients).
Detection of cryptic chromosomal abnormalities in
patients with secondary AML evolving from JAK2
V617F+ disease
SNP-A can also be used to identify lesions acquired during AML
evolution. We investigated cytogenetic implications of AML
transformation in 5 patients. In 2 patients with classical MPD
(#34 and #38), SNP-A showed two distinct modes of trans-
formation to AML. In patient #38, UPD9p was present at
diagnosis, consistent with a homozygous JAK2 V617F mutation.
However, upon transformation to AML, repeated SNP-A analysis
now showed the presence of a new, V617F- leukemic clone with
a normal chromosome 9 and previously absent micro-deletions on
both chromosomes 4 and 19 (Figure 2). In the second patient,
transformation was accompanied by the presence of UPD9p
(consistent with homozygous Jak2 mutation) and UPD7q. Both
lesions were present in blasts as well as in mature granulocytes
suggesting an evolution from within the JAK2 mutated clone
(Figure 3A, B, C).
We performed similar analysis of 3 MDS/MPD-U patients who
transformed to AML (Tables 1 & 2; patients #26, #28 and
#29). Similar to patient #38 above and in accordance with recent
published findings [29,30], patient #26 showed two distinct clones
upon transformation; one contributing to mature cell production
characterized by the V617F mutation and a second with wild-type
SNP Arrays in MDS/MPD-U
PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1225jak2 (data not shown). However, in 2 of 3 MDS/MPD-U patients
(Pts. #28 and #29), we identified the presence of a clone
possessing both the JAK2 V617F mutation and additional
chromosomal lesion(s) associated with AML transformation. This
result was obtained by comparison of SNP-A data from both
granulocytes and sorted CD34+ blasts (Figure 3D, E, F). More
interestingly, patient #29 seems to harbor 2 clones: one clone with
UPD9p that resulted in a homozygous JAK mutation and an AML
clone which possesses 1 mutated and 1 wild type jak2 allele.
Granulocyte idiograms demonstrated the presence of UPD9p
(confirming the homozygous V617F clone) and an otherwise
normal chromosome set. In CD34+ blasts, however, a normal
chromosome 9 was present but a new del6p was detected, likely
contributing to leukemic transformation. ARMS-PCR (Figure 3F,
right panel) showed a mutated jak2 (T) and wild-type allele (G) in
the blast fraction suggesting that the AML clone arose from a cell
heterozygous for the jak2 mutation.
DISCUSSION
Some cases of MPD show a pathophysiologic overlap with MDS
[21,22,31], and in some instances, the JAK2 mutation is present. A
significant clinical heterogeneity, ranging from common chronic
course to less frequent evolution to AML [13,16–18], exists among
classical MPD patients with the JAK2 V617F mutation, and is
even more diverse in patients with MDS/MPD overlap. It is
possible that some of this variability in clinical phenotype may be
related to the diverse spectrum of cytogenetic defects found in
these patients. The presence of these cytogenetic abnormalities, as
detected by SNP-A, supports the theory that MPD patients have
an underlying propensity to chromosomal breaks and subclonal
evolution. This feature may be particularly accentuated in patients
with MDS/MPD-U overlap, although only a minority of these
patients, perhaps with exception of RARS-t, harbor the V617F
mutation [20,22].
We have compared the results of MC and SNP-A karyotyping
in patients with MDS/MPD-U with and without the JAK2 V617F
mutation. SNP-A allowed for the detection of previously cryptic
chromosomal abnormalities in 19/30 patients with MDS/MPD-
U, including those who showed normal MC. In addition to gains
and deletions, SNP-A allowed for efficient detection of UPD. The
most illustrative example of this type is UPD9p itself, which was
found in all patients homozygous for the V617F mutation.
Figure 1. SNP karyograms confirm loss of heterozygosity in patients homozygous for JAK2 V617F. SNP-A based karyotypic analysis on
chromosome 9 for (A) a patient heterozygous for the JAK2 V617F mutation and (B,C) two patients homozygous for the JAK2 V617F mutation. (A,B
and C, left portion) Signal intensity and SNP karyograms for each corresponding patient; the blue line represents the average fluorescent signal
intensity of each SNP and oscillates around the diploid marker line; green tics represent heterozygous calls for each individual SNP. Areas of UPD are
associated with the absence of heterozygous calls and are highlighted by blue and pink bars. Extraneous calls in regions of UPD occur as a result of
contamination by non-clonal cells. UPD was confirmed by microsatellite analysis (data not shown). (C) In addition to chromosome 9, patient #36 also
exhibited a segmental deletion in chromosome 12 as indicated by decreases in the copy number and frequency of heterozygous calls. (A,B, and C,
right portion) Corresponding ARMS-PCR analysis of the JAK2 V617F mutation in each patient confirms heterozygous (A) and homozygous (B,C)
mutational status (gel images are cropped and enhanced).
doi:10.1371/journal.pone.0001225.g001
SNP Arrays in MDS/MPD-U
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..................................................................................................................................................
Pt. Age Sex Initial Diagnosis
Trans. to
AML (Y/N) Clinical features
JAK2 V617F
Genotype
MDS/MPD
(N=30)
1 65 F MDS/MPDu N Increased small megakaryocytes in clusters, pSTAT5+ staining in
megakaryocytes, fibrosis
G/G
2 60 M MDS/MPDu N Left-shifted leukocytosis, leukoerythroblastic changes, dyspalstic erythroid
series, dysplastic megakaryocytes, fibrosis
G/G
3 76 M MDS/MPDu N Increased dysplastic megakaryocytes, megaloblastoid dyserythropoiesis,
dysgranulopoiesis with hypogranular PMNs, fibrosis, increased mast cells
G/G
4 77 M MDS/MPDu N Increased dysplastic megakaryocytes, absent erythropoiesis, left-shifted
granulopoiesis, dysgranulopoiesis
G/G
5 65 F MDS/MPDu N Increased dysplastic megakaryocytes, fibrosis G/G
6 73 M MDS/MPDu N Mild to moderate dyserythopoiesis, fibrosis G/G
7 62 F RARSt N Dyserythropoiesis and ringed sideroblasts, dysplastic megakaryocytes G/G
8 72 M MDS/MPDu N Increased dysplastic megakaryocytes in clusters, marked fibrosis G/G
9 41 F MDS/MPDu N Dyserythropoiesis, left-shifted, dysplastic granulopoiesis G/G
10 80 M RARSt N Increased ringed sideroblasts, dyserythropoiesis, fibrosis, pSTAT5+ staining
in erythroid precursors and megakaryocytes, thrombocytosis
G/G
11 67 M MDS/MPDu N Dysplastic megakaryocytes, dysgranulopoiesis, fibrosis G/G
12 76 F MDS/MPDu N Dysplastic megakaryocytes, dyserythropoiesis, dysgranulopoiesis, fibrosis G/G
13 73 M MDS/MPDu N Dysplastic megakaryocytes, fibrosis G/G
14 73 M RARSt N Dysplastic megakaryocytes in clusters, ringed syderoblasts, fibrosis,
thrombocytosis
G/G
15 74 F RARSt N Dysmegakaryopoiesis, ringed sideroblasts, increased proerythroblasts,
thrombocytosis
G/G
16 60 M RARSt N Increased dysplastic megakaryocytes, numerous ringed sideroblasts,
fibrosis, thrombocytosis
G/T
17 60 F RARSt N Increased ring sideroblasts, dysmegakaryopoiesis, thrombocytosis G/T
18 76 M RARSt N Increased ringed sideroblasts, increased dyplastic large megakaryocytes,
megaloblastic erythropoiesis with mild megaloblastoid change, fibrosis,
thrombocytosis
G/T
19 75 F RARSt N Megaloblastoid dyserythropoiesis, increased ringed sideroblasts,
dysmegakaryopoiesis, fibrosis, thrombocytosis
G/T
20 79 M MDS/MPDu N Left shifted hyperplastic dysgranulopoiesis, increased dysplastic
megakaryocytes, fibrosis, monocytosis
G/T
21 70 M MDS/MPDu N Dysplastic megakaryocytes, splenomegaly G/T
22 76 F RARSt N leukocytosis with absolute monocytosis, thrombocytosis, numerous
ringed sideroblasts, fibrosis
G/T
23 67 F MDS/MPDu Y Erythroid dsplasia, dysplastic granulopoiesis, increased megakaryocytes,
fibrosis
G/G
24 71 M MDS/MPDu Y Megaloblastic erythropoiesis, left-shifted dysplastic granulopoiesis,
dysplastic megakaryocytes, fibrosis, hepatosplenomegaly
G/G
25 80 F MDS/MPDu Y Dysplastic granulocytopoiesis, megaloblastoid and dysplastic erythroid
maturation, dysplastic megakaryocytes
G/G
26 73 M MDS/MPDu Y Increased dysplastic megakaryocytes, dyserythropoiesis, fibrosis G/T
27 72 F MDS/MPDu Y Dysplasia involving all lineages, fibrosis, increased megakaryocytes G/T
28 54 M MDS/MPDu Y Increased dysplastic megakaryocytes in clusters, fibrosis T/T
29 65 M MDS/MPDu Y Left-shifted, leukocytosis, normocytic anemia, thrombocytopenia,
splenomegaly
T/T
30 62 F MDS/MPDu Y Increased dysplastic megakaryocytes in clusters, fibrosis T/T
MPD (N=8) 31 76 F PV N Polycythemia G/T
32 78 M PV N Polycythemia G/T
33 81 F PV N Polycythemia G/T
34 62 M PV Y Polycythemia T/T
35 63 F PV/IMF N Fibrosis, polycythemia, leukoerythroblastic changes G/T
36 67 M IMF N Fibrosis, splenomegaly, leukoerythroblastic changes T/T
37 56 M IMF Y Fibrosis, splenomegaly, leukoerythroblastic changes T/T
38 77 M IMF Y Fibrosis, splenomegaly, leukoerythroblastic changes T/T
MDS/MPD-U: myeloproliferative disorder/myelodysplastic syndrome overlap, unclassifiable; RARSt: refractory anemia with ringed sideroblasts and thrombocytosis; PV:
polycythemia vera; IMF: idiopathic myelofibrosis,
doi:10.1371/journal.pone.0001225.t001
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PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1225Table 2. Cryptic chromosomal abnormalities identified in patients with MDS/MPD-U and secondary AML with and without the
JAK2 V617F mutation.
..................................................................................................................................................
Pt. Lesions detected by Metaphase Cytogenetics (MC) Additional Lesions found by SNP-A (New lesions not detected by MC)
MDS/MPD 1 46,XX,del(5)(q12q33)[cp7] NAL
2 46,XY[20] add (16)(q23.1)
3 46,XY[20] NAL
4 46,XY,del(7)(q11.2),del(20)(q11q13),-21,+r[cp20] del(7)(p12.3-p14.1), del(7)(q11.22-qter), del(11)(p15.4-p15.5),
add(21)(complex), UPD(22)(q11.21-qter)
5 46,XX[20] add(1)(p32.2), add(X)(p22.31)
6 46,XY[20] add(2)(p16.1), del(6)(q16.1)
7 46,XX[20] NAL
8 46,XY,+8[9]/46,XY[11] UPD(6)(p21.32-p22.2)
9 46,XX,t(6;9)(p23;q34)[20] UPD(11)(q14.1-q14.2), UPD(12)(p11.21-p12)
10 46,XY[20] NAL
11 46,XY,del(20)(q11.2q13.3)[19]/46,XY[1] del(11)(q14.1), del(12)(p13.1-p13.31)
12 46,XX,del(4)(p14),del(5)(q13q33),del(12)(q23),del(13)(q14q22),-
I(17)(q10)[8]/46,idem,t(2;7)(p12;q36)[10]/47,XX,del(4)(p14),del-
(5)(q13q33),add(11)(p15),add(12)(p13),del(13)(q14q22),I(17)-
(q10),+mar[2]
del(2)(p26.1-p26.2), del(4)(p15.1), del(7)(q34), del(11)(p15.4-pter),
del(12)(q24.31), del(13)(q22.1-q22.2), del(13)(q33.1), del(17)(p13.1),
del(21)(q21.2-q22.11)
13 46,XY[11] UPD(3)(p23-p24.1), UPD(3)(q12.3-q13.12), UPD(11)(q13.4-qter)
14 46,XY[20] NAL
15 47,XX,+8[4]/46,XX,[16] NAL
16 46,XY[20] NAL
17 46,XY, del(5)(q) [20] NAL
18 46,XY[20] NAL
19 46,XX,inv(9)(p11q12)[20] UPD(1)(p11.2-pter), del(2)(p16.2), del(22)(q11.23)
20 46,XY [10]; 47,XY,+8,[9]; 46,XY,del(20)(q11.2) [1] NAL
21 46,XY,del(2)(p22),inv(9)(p12q13),del(20)(q12)[4] del(8)(q11.23-q12.1), add(9)(p12-pter)
22 46,XX[20] NAL
23 46,XX,der(3)(3pter-.3q13.1::3q21-.3q21::3q24-.3qter),+8[22] del(3)(q13.1-q21.3), del(9)(p23), UPD(11)(q12.2-q13.3)
24 48,XY,+8[6]/46,XY[14] UPD(1)(q25.2-25.3)
25 46,XX[20] UPD(11)(p), del(16)(p12.1)
26 47,XY,+8[14] del(2)(q23.3-q24.1), del(4)(q26.1), del(6)(q23.2-q23.3), +13, +17q, -17p*
27 44-45,XX,del(5)(q13q33),-6,-10,-13, add(14)(q32),
add(17)(p11.2),add(20)(p11.2),+r,+mar[cp3]/46,XX[6]
del(9)(p21.1)
28 47,XY,+8[12]/46,XY[8] UPD(9)(p13.2-pter)
29 46,XY,der(6)t(1;6)(q25;p23)[14]/46,XY[6] del(4)(q24), UPD(9)(p21.1-pter)
30 47,XY,del(3)(q21q26.2),+5,del(5)(q32)x2,add(7)(q22),
del(7)(q?32),inv(12)(q13q15)[20]
add(3)(q21.3), del(3)(q21.3), add(5)(q13.3-pter), del(5)(q13.3), del(5)(q31.2),
del(7)(q22.1), del(7)(q34), del(7)(q36.1), UPD(9)(p13.3-pter), del(10)(p12.1)
MPD 31 49,XX,+8,+9,+21[8]/46,XX[12] NAL
32 N/A del(13)(q12.3-q31.1)
33 46,XX[20] del(18)(q12.1-q12.2)
34 46,XY[20] UPD(7)(q22.1-qter), UPD(9)(p13.3-pter)
35 N/A del(1)(p36.21-p36.32), del(5)(q21.3-q33.3), del(9)(p13.2-p21.2),
del(9)(q21.13-q21.33), del(9)(q22.31-q31.1)
36 46,XY[20] UPD(9)(p21.3-pter), del(12)(p13.1-p13.31)*
37 46,XX,del(13)(q12q22)[15]/46,XX[5] UPD(9)(p13.3-pter), UPD(11)(q12.3-qter), del(13)(q13.2-q31.1)
38 46,XY[20] UPD(9)(p21.2-pter)*
NOTE: copy number lesions identified by MC were confirmed by SNP-A. Any significant changes in the size of regions initially reported by MC are noted in the right-
hand column along with other additional lesions found by SNP-A.
Abbreviations: N/A: no aspirate obtained; NAL: no additional lesions found; *SNP-A data obtained using granulocyte DNA.
doi:10.1371/journal.pone.0001225.t002
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1225Recently, the utility of SNP-A for identification of UPD9p was
demonstrated in both MPD [28] and MDS [7,8] and our results
show that UPD due to mitotic recombination can affect not only
the p-arm of chromosome 9 but also other regions of the genome.
While there was an abundance of UPD found in these patients, no
significant overlap occurred, perhaps due to the size of the cohort
studied. However, one region of overlap, located on chromosome
11q14.1, harbors genes of particular interest, including rab30
(*605693), a proto-oncogenic member of the RAS family, and
perhaps most notably, gab2 (*606203), which encodes an adaptor
protein that mediates the interaction between STAT5 and
phosphatidylinositol-3 kinase (PI3k) in activation of the PI3k/Akt
pathway [32,33].
Copy-neutral loss of heterozygosity has been described in
several malignancies [1–5] but due to the inability of MC to
identify UPD, it has remained undetected in many patients.
Previously, we have demonstrated that UPD is quite prevalent in
patients with MDS and can be found in approximately 30% of
cases studied by either 50K or 250K SNP-A [8].
In general, there was no difference in the types of lesions present
in patients with and without the V617F mutation; however, UPD
was present more often in patients who were negative for the
mutation. As expected, UPD9p was not encountered in patients
either wild-type or heterozygous for the JAK2 mutation.
In the course of our study, we have observed a number of
patients who progressed from MDS/MPD-U and MPD to AML.
SNP-A helped to delineate the origin of the AML clone. The
pathogenesis of AML in patient #26 and #38 is consistent with
previous reports which show that in a majority of cases,
transformation to AML in patients with classical MPD occurs in
a stem cell with a wild-type jak2 gene [29,30]. However, we have
found that in some instances (pts. #28, #29, and #34), AML does
originate from a stem cell with a mutant jak2 gene. The
transformation process is often associated with the acquisition of
additional defects (e.g. del6p as demonstrated in patient #29, or
micro-deletions of chromosomes 4 and 19 as demonstrated in
patient #38).
Our ability to detect cryptic lesions is related to the technical
advantages of SNP-A-based karyotyping, which allows for the
Figure 2. SNP-A can be used to identify lesions acquired during AML evolution. SNP-A karyograms demonstrate that before transformation (A),
patient #38 showed only UPD9p at initial diagnosis as a sole abnormality (consistent with a homozygous JAK2 V617F mutation) along with normal
chromosomes 4 and 19. However, after transformation to AML (B), repeated SNP-A analysis showed the presence of a V617F- leukemic clone with
a normal chromosome 9 and newly-acquired micro-deletions on both chromosomes 4 and 19.
doi:10.1371/journal.pone.0001225.g002
Table 4. List of commonly deleted regions in MDS/MPD-U
patients.
......................................................................
Lesion N
del(13)(q14-q22) 3
del(7)(q22.1)/del(7)(q34)/del(7)(q36.1) 3
del/UPD(11)(q14.1) 3
del/UPD(11)(p15.4-p15.5) 3
del(20)(q11.2-q12) 4
del(5)(q13-q33) 5
add/UPD(9)(p13.3-pter) 4
Trisomy 8 7
doi:10.1371/journal.pone.0001225.t004
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Table 3. UPD found in MDS/MPD-U patients both positive and
negative for the JAK2 V617F mutation.
......................................................................
V617F+ V617F-
UPD N UPD N
UPD(1) 1 UPD(1) 1
UPD(9) 3 UPD(3) 1
UPD(6) 1
UPD(11) 4
UPD(12) 1
UPD(22) 1
doi:10.1371/journal.pone.0001225.t003
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1225Figure 3. Karyotypic analysis of AML evolution in patients with the JAK2 V617F mutation. Karyograms illustrate the contributing lesions in patient
#34 (A, B) and patient #29 (D, E). In panels C and F, microsatellite analysis confirms the UPD for patients #34 and #29, respectively. In patient #34
(A,B,C), only one distinct clone was identified: in both granulocytes (A) and blasts (B), loss of heterozygosity calls on chromosome 9 confirms UPD9p,
consistent with the homozygous JAK2 V617F mutation. In addition, both cell types also possess UPD on 7q. (C, left portion) Microsatellite analysis of
blasts and granulocytes confirms LOH on 9p in both cell types. (C, right portion) Electrophoresis gel of ARMS-PCR in patient #34 also shows
a homozygous JAK2 V617F mutation in both granulocytes and blasts (gel image is cropped and enhanced). In patient #29 (D,E,F), two distinct clones
were identified using DNA isolated from both granulocytes and CD34+ blasts. In granulocytes (D), UPD9p is consistent with a homozygous JAK2
V617F mutation while analysis of chromosome 6 did not reveal any abnormalities. LOH on chromosome 9 was not completely resolved in the
karyogram obtained; however, comparative analysis of granulocytes and lymphocytes confirmed allelic imbalance (red line: lymphocytes, green line:
granulocytes). In contrast, when CD34- selected blasts were analyzed (E), UPD9p was not identified while a segmental deletion on chromosome 6 was
found. In panel F, microsatellite analysis and electrophoresis gel of ARMS-PCR demonstrate the presence of homozygosity for the JAK2 V617F
mutation in granulocytes but heterozygosity in CD34+ cells.
doi:10.1371/journal.pone.0001225.g003
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1225identification of smaller lesions and copy number neutral changes
(UPD); however, one drawback to SNP-A karyotyping is its
inability to recognize balanced translocations [34].
In order to assess the significance of clonal chromosomal lesions
present in patients with MDS/MPD-U, study of normal control
specimens is essential. We have found a large number of known
copy number polymorphisms detected in controls, but UPD was
only found in 4/58 patients and tended to be much smaller than
that seen in patients. For the purpose of our study, all copy
number changes seen in patients were compared to those
described both in public databases and those present in our own
control group. Subsequently, all copy number variations found in
normal controls were eliminated from our patient samples and
analysis. In previous studies, we have extensively validated the
results obtained by 50K and 250K arrays using FISH, MC,
microsatellite PCR, and TaqMan PCR for copy number de-
termination [6,8]. However, the sensitivity of SNP-A for the
number of clonal cells in the sample is limited: as tumor content
decreases, LOH detection rate steeply declines, and with ,20–
30% tumor cells, no LOH can be detected, even when complete
genotype information for both tumor and paired constitutive DNA
is obtained [28].
In summary, our results demonstrate the applicability of SNP-
A-based karyotyping for detecting clonal cytogenetic abnormalities
in MDS/MPD-U. This new technology allows for precise
definition of chromosomal aberrations, including copy-neutral
LOH, and complements MC in detecting chromosomal lesions in
MDS/MPD-U. Our results demonstrate that UPD is a common
form of LOH in both JAK2 V617F+ and V617F- disorders and is
not restricted only to chromosome 9p but can affect other regions
which may potentially point towards causative genes.
MATERIALS AND METHODS
Patients
Bone marrow aspirates were collected from patients with MDS/
MPD-U (N=30) and MPD (N=8) (mean age 69 years; range 41–
81) seen between 2002–2007. Patients were grouped according to
the World Health Organization (WHO) classification system [35]
(Table 1). For the purpose of the study, we have focused our
analysis on patients with MDS/MPD. This includes MDS/MPD-
U, RARS-t, CMML and atypical CML. However, CMML and
atypical CML represent a phenotypically distinct subtype of
MDS/MPD and have not been included in this study. In 5
patients who transformed to AML we studied both original clones
as well as leukemic blasts. Informed consent for sample collection
was obtained according to protocols approved by the Cleveland
Clinic IRB. Aspirates obtained from 58 healthy individuals (mean
age 43 years; range 27–61) were used as controls.
Cytogenetic analysis
Cytogenetic analysis was performed on marrow aspirates accord-
ing to standard methods. Chromosome preparations were G-
banded using trypsin and Giemsa (GTG), and karyotypes were
described according to ISCN [36].
Cell separation
In some experiments, granulocytes were used as a source of DNA
for analysis and were isolated during density centrifugation
separation from pelleted cells. For separation of CD34+ cells
and CD3+ lymphocytes, blood or marrow mononuclear cells were
isolated using Ficoll density gradient centrifugation and then
separated using magnetic beads (StemCell Technologies, Vancou-
ver, Canda) on the RoboSep Instrument (StemCell Technologies)
according to the protocol provided by the manufacturer. The
purity of isolated cells was .95% as measured by flow cytometry
(Coulter Elite, Hielah, FL).
DNA extraction
DNA was extracted from whole bone marrow with the
ArchivePure DNA Blood Kit (5Prime, Gaithersburg, MD, USA).
Red blood cell lysis solution was added to whole bone marrow at
a 3:1 ratio and incubated with shaking for 10 minutes. The cells
were pelleted and the DNA extracted as per the manufacturer’s
instructions. The concentration of the DNA was obtained using
a ND-1000 spectrophotometer (NanoDrop, Wilmington, DE,
USA) and the quality determined by gel electrophoresis.
Allele-specific polymerase chain reaction (PCR)
The status of the JAK2 V617F mutation was determined by
a DNA tetra-primer ARMS assay as previously described [37].
The sequences of the primers were as follows: 59-GCATTTG-
GTTTTAAATTATGGAGTATATG-39,5 9-GTTTTACTTA-
CTCTCGTCTCCACAAAA-39,5 9-AAGCACATTGTATCCT-
CATCTATAGTCA-3, 59-GAATAGTCCTACAGTGTTTTC-
AGTTTCA-39. Wild-type G/G genotype generates 2 bands on
gel electrophoresis at 379bp and 201bp, homozygous T/T:2
bands at 379 bp and 234 bp, and heterozygous G/T: all 3 bands.
Gels were photographed, cropped, and enhanced using the
Bio-Rad Gel Doc XR machine and Quantity One 4.5.2 software
(Bio-Rad, Hercules, CA).
SNP-A analysis
The Gene Chip Mapping 250K Assay Kit (Affymetrix, Santa
Clara, CA) was used for SNP-A analysis. Following Nsp I
digestion, fragmented DNA was ligated to adaptor followed by
PCR amplification. The PCR product was hybridized to the
GeneChip Mapping 250K Nsp Array, processed with the Fluidic
Station and the Gene Chip Scanner 3000 (Affymetrix). Only DNA
samples with a call rate of .90% were used. To determine the
minimal clonal size that can be detected by SNP-A, dilution
studies of trisomy 21 DNA with normal diploid DNA were
performed; clones spanning more than 25–50% of the total cell
population can be detected. Unlike comparative genomic
hybridization, SNP-A does not require reference DNA as it
obtains copy number and loss of heterozygosity calls through
analysis of hybridization frequencies using probes designed to
detect individual SNP alleles [34].
Microsatellite and gene copy number (CN) analysis
In general, SNP-A as a karyotyping platform was validated in our
previous studies with regard to sensitivity, resolution, and ability to
detect clonal vs. germ line chromosomal defects [8,34]. When
appropriate, regions of LOH for this study were confirmed by
microsatellite (MS) polymorphism analysis. Primer sequences were
obtained from the NCBI database (http://www.ncbi.nlm.nih.gov).
Forward primers were modified at the 59 end with FAM
fluorescent dye. DNA was amplified and amplicons analyzed
using ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster
City, CA). CN analysis was performed by microsatellite analysis
using a Real-Time TaqMan chemistry protocol [38]. The probe
for detection of CA repeats was designed as a 21-bp oligomer
containing GT repeats with FAM and Black Hole Quencher
modifications on 59 and 39 ends, respectively. All reactions were
performed in triplicate using the D12S1699 amplicon as an
endogenous control.
SNP Arrays in MDS/MPD-U
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Signal intensity was analyzed and SNP calls determined using
Gene Chip Genotyping Analysis Software Version 4.0 (GTYPE).
CN was investigated using a Hidden Markov Model and CN
Analyzer for Affymetrix GeneChip Mapping 250K arrays (CNAG
2.0) [39]. Segmental LOH was identified by a statistical assessment
of the likelihood that consecutive SNP loci would exhibit
heterozygosity given the corresponding allelic frequency of
particular SNP in the normal population (CNAG). The two-sided
Fisher’s Exact test was used to analyze the difference between the
distribution of dichotomized variables among the groups.
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